08:21 AM EDT, 10/31/2025 (MT Newswires) -- Nanobiotix ( NBTX ) said Friday it has entered into a royalty-based financing agreement with HealthCare Royalty worth up to $71 million to support its growth and extend its cash runway into early 2028.

Under the deal, the company said it will receive $50 million upfront at closing and an additional $21 million a year later if certain conditions are met.

Repayment to HealthCare Royalty will come from a portion of royalties on the first $1 billion of net sales and certain milestone payments, capped at $124 million if repaid by 2030 or $178 million if repaid later, the company said.

A royalty-only tail period will continue for up to 10 years following the first US commercial sale of NBTXR3, also known as JNJ-1900 under a license agreement with Johnson & Johnson's ( JNJ ) Janssen Pharmaceutica, it added.

Shares of the company were up more than 13% in recent premarket activity Friday.